Category: Production-Defect Anemia

  • Anemia Associated With Systemic Disease

    As noted in Chapter 3, anemia associated with various chronic diseases is usually normocytic and either normochromic or hypochromic. The serum iron and total iron-binding capacity (TIBC) are typically both decreased. In 100 consecutive patients in our hospital who had chronic disease and red cell or iron-related biochemical abnormalities, 68 had anemia with normal mean corpuscular volume (MCV), decreased serum iron, and decreased TIBC; 7 had no anemia; 9 had normal serum iron levels; 6 had normal TIBC; and 7 had decreased MCV (with normal serum ferritin levels). Others have reported that decreased MCV may occur in up to 25% of cases.

    Chronic renal disease

    Anemia of moderate degree is frequently found in association with uremia. Some investigators claim it is almost always present when the blood urea nitrogen (BUN) level is persistently more than twice normal, and it often appears before this level is reached. Patients with prolonged but potentially reversible azotemia (e.g., acute renal failure) often develop anemia until the kidneys recover. Transient types of azotemia usually do not produce anemia unless azotemia is prolonged or due to the underlying cause itself. The anemia of actual renal insufficiency develops regardless of the cause of the uremia.

    The peripheral blood RBCs are usually normocytic-normochromic; there is often mild to moderate anisocytosis. Varying numbers of burr cells (triangular shrunken RBCs with irregular pointed projections from the surface (Chapter 2) are found in some patients. In some cases there is mild hypochromia and, occasionally, some degree of microcytosis. On the other hand, mild macrocytosis may be present in a few patients.

    Bone marrow usually shows normal cellularity, although in some cases there is mild RBC hypoplasia. Marrow iron is adequate. The serum iron level is usually normal, but about 20%-30% of patients have low serum iron levels even though they do not have iron deficiency. Most of these patients also have a low or low-normal TIBC typical of chronic disease anemia (Chapter 3). Reticulocyte counts are usually normal; occasionally, they may be slightly elevated.

    The pathophysiology involved is not well understood. The primary known abnormality is a lack of incorporation of iron into RBCs within the bone marrow. There is depression both of hemoglobin synthesis and of formation and release of mature RBCs into the peripheral blood. In 10%-15% of patients there is also decreased RBC survival in the peripheral blood, although the hemolytic aspect is usually not severe. There is, however, a rare condition known as the hemolytic-uremic syndrome that features a severe microangiopathic (RBC fragmentation) hemolytic anemia. Patients in the late stages of uremia may have a bleeding tendency due to coagulation defects, most commonly thrombocytopenia. Platelet function may be abnormal even with normal numbers of platelets. The effect of hemorrhage, if it occurs, is separate and additional to the anemia of chronic renal disease.

    Anemia of neoplasia

    Anemia develops in 60%-90% of patients with moderate or far-advanced cancer. The anemia of neoplasia is usually normocytic with normal reticulocyte counts, unless there is hemorrhage or chronic blood loss. Cytotoxic chemotherapy is accompanied by a macrocytic MCV in 30%-40% (12%-82%) of patients. A hemolytic component is present in a considerable minority of patients, but hemolysis is generally mild and is not detectable except with radioisotope RBC survival procedures. Occasionally, hemolysis may be severe, especially in patients with chronic lymphocytic leukemia and malignant lymphomas. In one series, anemia was ascribed to a combination of decreased RBC survival and decreased marrow production in 56% of patients, to blood loss in 29%, and to marrow metastases by the tumor in 13%. Thrombocytopenia may be found in certain types of leukemia and in myelophthisic anemias. Fibrinolysins appear in occasional cases of widespread malignancy, most often prostate carcinoma.

    Anemia of infection

    Mild to moderate anemia is frequently associated with subacute or chronic infection. The mechanism of this anemia is not well understood, but there seems to be a decreased rate of erythropoiesis, coupled in some patients with slightly shortened RBC survival time and failure to use iron normally. The anemia of infection usually does not develop unless the infection lasts 1 month or more, although it may develop rapidly in patients with severe acute infection such as septicemia. Chronic infection producing anemia generally is of at least moderate severity. Infections in which anemia is likely to develop include bronchiectasis, salpingitis, abscess of visceral organs or body cavities, and severe pyelonephritis. Anemia is a common finding in subacute bacterial endocarditis and in the granulomatous diseases such as tuberculosis and sarcoidosis. The anemia is usually normocytic and normochromic, but sometimes it is hypochromic. Reticulocyte counts are usually normal, although occasionally they may be slightly increased. Bone marrow aspiration shows either normal marrow or hyperplasia of the granulocytes. The serum iron level is usually low or low-normal, and plasma TIBC is reduced (in iron deficiency anemia the TIBC is elevated).

    Aplastic anemia is a rare complication of type C (non-A, non-B) hepatitis virus infection.

    Rheumatoid-collagen disease group

    Rheumatoid-collagen diseases are frequently associated with mild to moderate normocytic anemia. In one study 40% of males and 63% of females with rheumatoid arthritis were anemic. Active disease is more likely to produce anemia. Incidence of coexistent iron deficiency ranges from 10%-30%. Reticulocytes are usually normal, and the bone marrow is unremarkable. In many patients there apparently is decreased erythropoiesis with a slightly shortened RBC survival time, but there is some disagreement regarding frequency of decreased RBC survival. About 5%-10% of patients with rheumatoid arthritis have splenomegaly, which may be associated with cytopenias.

    Chronic liver disease

    The type and frequency of anemia in liver disease vary with the type and severity of hepatic dysfunction, but anemia has been reported in up to 75% of patients. It is most frequently seen in far-advanced cirrhosis. Extensive metastatic carcinoma of the liver may produce the same effect, although it is difficult to say whether the liver involvement or the neoplasm itself is the real cause. About 30%-50% (8%-65%) of patients with anemia have macrocytosis; about one third are normocytic. Some have hypochromia due to GI blood loss. Target cells in varying numbers are a frequent finding on peripheral blood smear.

    Macrocytic anemia in liver disease is most often found in severe chronic liver damage; this type of anemia is not frequent in acute liver disease, even when severe, or in chronic disease of only slight or mild extent. A small but significant percentage of hepatic macrocytic anemias are megaloblastic, usually secondary to folic acid dietary deficiency, although most are not megaloblastic and are not corrected by folic acid treatment. A peripheral blood smear may be macrocytic even when there is a normal hemoglobin or hematocrit reading, and sometimes even with a normal MCV.

    GI bleeding occurs in a considerable number of cirrhotic patients; often it is very slight and intermittent. Esophageal varices are present in some. Other lesions may be demonstrated in other patients. In a considerable proportion of cases the source of bleeding cannot be located.

    Hypersplenism occurs in some patients with portal vein hypertension and its resulting splenic congestion. Thrombocytopenia, usually mild, is reported to occur in up to 50% of patients with cirrhosis, and other cytopenias may sometimes develop. In severe chronic (or massive acute) liver disease, coagulation problems may result from insufficient hepatic synthesis of several blood coagulation factors.

    Some liver-diseased patients have shortened RBC survival demonstrated only by using radioactive isotope studies and show no evidence of GI bleeding. There is no clinical or laboratory evidence of hemolysis otherwise. About 3%-5% develop Zieve’s syndrome, a combination of hyperlipemia, cirrhosis, and microangiopathic hemolytic anemia. This hemolytic anemia is associated with reticulocytosis and the other classic features of hemolysis.

    Unless blood loss is a factor, and excluding megaloblastic anemia, the bone marrow is unremarkable in liver disease and the reticulocyte count is usually close to normal. Not all cases of anemia associated with liver disease can be explained.

    Hypothyroidism

    Anemia is found in 30%-50% (21%-60%) of hypothyroid patients. About 15% (8%-20%) of the anemic patients have macrocytosis, most of the remainder having either normocytic-normochromic or normocytic-hypochromic indices. A small percentage have hypochromic-microcytic RBCs.

    The hypochromic anemia of hypothyroidism responds to a combination of iron and thyroid hormone preparation. The iron deficiency component is frequently produced by excessive menstrual bleeding. In patients without demonstrable blood loss it is speculated that decreased intestinal iron absorption may occur, since thyroid hormone is known to affect intestinal carbohydrate absorption. Most of the macrocytic cases respond only to thyroid hormone. In these patients the bone marrow is not megaloblastic and is sometimes slightly hypocellular. The reticulocyte count is usually normal. Isotope studies reportedly show normal RBC survival time in most cases. Lack of thyroid hormone seems to have a direct effect on erythropoiesis, since thyroid hormone therapy cures both the myxedema and the anemia (unless there is superimposed iron deficiency). A minority of patients with macrocytic anemia have folic acid or vitamin B12 deficiency, presumably secondary to decreased intestinal absorption. Thyroid hormone is required in addition to folic acid or vitamin B12. About 5% have actual pernicious anemia, with megaloblastic bone marrow.

    Comments on chronic disease anemia

    To conclude this discussion, it should be noted that the normocytic-normochromic anemia of systemic disease has often been called“simple chronic anemia,” although the pathophysiology is far from simple. The disease categories listed in this chapter are only the most common. In many cases, the diagnosis is one of exclusion; the patient has anemia for which no definite etiology can be found, so whatever systemic disease he or she has is blamed for the anemia. Some investigators restrict the diagnosis of chronic disease anemia to those who have decreased serum iron and TIBC. Regardless, it is important to rule out treatable serious diseases. This is especially true for hypochromic anemias (in which blood loss might be occurring) and macrocytic anemias (which may be due to vitamin B12 or folic acid deficiency). A normocytic-normochromic anemia may be due to an occult underlying disease, such as malignant lymphoma or multiple myeloma.

  • Hypoplastic Marrow

    Anemia due to inadequate erythropoiesis without factor deficiency may be classified in several ways. One system is based on the mechanism involved, including (1) marrow failure to incorporate adequate supplies of hematopoietic raw materials (e.g., iron) into red blood cell (RBC) precursors, (2) failure to release mature RBCs from the marrow, or (3) destruction of RBC precursors in the marrow. From a clinical point of view, it is easier to divide production-defect anemias into two categories: those due to a hypoplastic bone marrow and those with normally cellular marrow that are associated with certain systemic diseases.

    Conditions that produce a hypoplastic marrow affect the bone marrow directly either by actual replacement or by toxic depression of RBC precursors. Bone marrow examination is the main diagnostic or confirmatory test.

    Replacement of marrow by fibrosis. This condition, commonly termed myelofibrosis, is usually idiopathic and leads to a clinical syndrome called myeloid metaplasia. The peripheral blood picture is similar in many ways to that of chronic myelogenous leukemia. Many include this condition with the myeloproliferative syndromes.

    Replacement of marrow by neoplasm. The types of tumors most commonly metastatic to bone marrow, the laboratory abnormalities produced, and the main hematologic findings are described in Chapter 33. The anemia of neoplasia is usually normocytic and normochromic. Iron deficiency anemia secondary to hemorrhage may be present if the tumor has invaded or originated from the gastrointestinal (GI) tract. Besides extensive marrow replacement (myelophthisic anemia), neoplasia may produce anemia with minimal bone involvement or even without any marrow metastases; in these patients, there seems to be some sort of toxic influence on the marrow production and release mechanism. In occasional cases of widespread neoplasm, a hemolytic component (shortened RBC life span) has been demonstrated.

    Multiple myeloma is a neoplasm of plasma cells that is difficult to distinguish for classification purposes from leukemia on one hand and malignant lymphoma on the other. Myeloma initially or eventually involves the bone marrow and produces a moderate normocytic-normochromic anemia. Despite proliferation of plasma cells in the bone marrow, appearance of more than an occasional plasma cell in the peripheral blood is very uncommon. Peripheral blood RBCs often display the phenomenon of rouleau formation, a piling up of RBCs like a stack of coins. This is not specific for myeloma and is most often associated with hyperglobinemia.

    Aplastic anemia. Aplastic anemia is defined as peripheral blood pancytopenia (decrease in RBCs, white blood cells [WBCs], and platelets below population reference range) due to below-normal numbers and function of bone marrow cell precursors without cytologic marrow abnormality or marrow replacement by fibrosis or malignancy. Among the various etiologies are agents that predictably damage the bone marrow (e.g., radiation, certain chemicals such as benzene, and certain cytotoxic antitumor drugs). Another category, sometimes called idiosyncratic or acquired aplastic anemia, includes medications or chemicals that ordinarily do not produce cytopenia. Effects of some medications in this group are dose-related (e.g., chloramphenicol) and in others occur completely unpredictably. A third category of aplasia appears to have some autoimmune component. This includes aplasia (usually temporary) that uncommonly occurs in association with certain viral infections (e.g., parvovirus B-19, Epstein-Barr, rubella, herpes zoster-varicella) and a permanent type rarely seen in non-A, non-B (type C) hepatitis virus infection. A fourth category, probably related to category 3, might include aplasia associated with pregnancy or thymoma (the latter most often affecting RBCs only). The aplastic“crisis” of sickle cell anemia might also fit here. Some of these temporary aplastic crises may be due to parvovirus B-19 infection. A fifth category includes congenital diseases in which aplasia appears with varying frequency, of which the best known are Fanconi’s syndrome and the Diamond-Blackfan syndrome. Finally, some investigators create a more controversial category into which they place certain conditions involving bone marrow that frequently, but not always, develop into typical hematopoietic malignancies. Even more controversial is the status of other hematopoietic or nonhematopoietic malignancies that affect bone marrow function without actual marrow involvement.

    About 50% (in some reports, up to 70%) of aplastic anemia cases are unexplained or the cause is unproven. To make matters even more difficult, in some cases marrow aplasia may develop days or weeks after beginning treatment or exposure to the causative agent; and in some cases it may appear some time after exposure has ceased (in the case of radiation, even years later). Also, certain other conditions, such as hypersplenism, megaloblastic anemia, or marrow replacement by tumor, can simulate aplastic anemia.

    A great variety of drugs and chemicals have been reported to cause idiosyncratic reactions. The effects range from pancytopenia to any combination of single or multiple blood element defects. Bone marrow aspiration usually shows a deficiency in the particular cell precursor involved, although, especially with megakaryocytes, this is not always true. Patients most often recover if they can be supported long enough, although a considerable number die of superimposed infection.

    The drugs most often implicated in idiosyncratic reaction aplastic change are listed here according to blood element defect:

    Pancytopenia. Chloramphenicol (Chloromycetin), phenylbutazone (Butazolidin), indomethacin, mephenytoin (Mesantoin), gold preparations, nitrogen mustard compounds (e.g., busulfan [Myleran]) and other antileukemic drugs. In addition, chloramphenicol may produce the“gray syndrome” in premature infants and newborns.

    Leukopenia. Chlorpromazine (Thorazine), promazine (Sparine), phenylbutazone, thiouracil, antileukemic drugs, sulfonamides.

    Thrombocytopenia. Quinidine, nitrofurantoin (Furadantin), sulfonylureas, chlorothiazide.

    Aplastic anemia is most often normocytic-normochromic. Reticulocyte counts are usually low (although they sometimes are slightly elevated if the patient is in a recovery phase). About one third of aplastic anemia patients have a macrocytic peripheral blood smear.

    As noted, bone marrow aspiration is usually essential for diagnosis and can be used to follow any response to therapy. However, certain problems are associated with this method of diagnosis and must be taken into account. A false impression of marrow hypocellularity may be produced by hemodilution of the marrow specimen, by aspiration at a place that has unusually large amounts of fatty tissue, and by poor slide preparation technique. An occasional completely dry puncture may occur in normal persons due to considerable variability in the bone marrow distribution. Therefore, the diagnosis should never be made on the basis of a single failure to obtain marrow. Also, a bone marrow biopsy specimen, or at least a clot section (clotted marrow aspirate, processed as an ordinary histologic specimen), is more reliable than a smear for estimating cellularity. This is especially true for megakaryocytes. On the other hand, a smear is definitely more valuable for demonstrating abnormal morphology. Both can usually be done at the same time.

    Certain conditions may be associated with episodes of transient bone marrow RBC hypoplasia. These include congenital spherocytosis, sickle cell anemia, and RBC hypoplasia associated with thymoma. Aplastic pancytopenia may occur in paroxysmal nocturnal hemoglobinuria, either preceding onset of the disease or after onset as a transient episode.

    Pancytopenia in children may be caused by Fanconi’s anemia or Diamond-Blackfan congenital hypoplastic anemia. Fanconi’s anemia is an autosomal recessive disorder characterized by pancytopenia and congenital abnormalities such as short stature, web neck, cleft lip, mental retardation, and renal anomalies. More than 10% of peripheral blood lymphocytes display chromosome abnormalities. Anemia may appear in children up to age 10 years with the disease. Diamond-Blackfan syndrome also has an autosomal recessive inheritance pattern and displays congenital anomalies, but it consists of pure RBC aplasia, and onset of anemia occurs either at birth or by age 6 months.

    In children, apparent aplastic anemia or pancytopenia must be differentiated from acute leukemia.